news
CHMP’s September 2023 meeting highlights
In its September 2023 meeting, the EMA’s human medicines committee (CHMP) recommended nine medicines for approval and the extension of therapeutic indications for 11 medicines.
List view / Grid view
influenza A
news
Plant “biofactories” produce proteins for potential COVID-19 vaccine
Transiently infecting tobacco plants, researchers were able to produce recombinant proteins that could be developed into COVID-19 vaccines.
news
Phase I trial of mRNA-based influenza vaccine begins
The trial will assess a monovalent mRNA-based vaccine candidate against seasonal influenza caused by the A/H3N2 strain.
news
FDA grants Emergency Use Authorisation to Abott’s SARS-CoV-2, influenza and RSV test
The PCR based Alinity™ m Resp-4-Plex molecular assay can detect and differentiate SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV).
news
EIB to support COVID-19 therapy with €24.5 million investment
The European Investment Bank (EIB) will provide Immunic with up to €24.5 million to support the ongoing development of IMU-838, a potential COVID-19 therapy.
news
FDA approves AUDENZ™, an adjuvanted Influenza A pandemic vaccine
The US FDA has approved AUDENZ, a vaccine formulated with MF59® adjuvant, as an Influenza A H5N1 vaccine that can be quickly deployed in the event of a pandemic.
news
Influenza A vaccine enters Phase IIb trial
Novel influenza A vaccine has been administered to first patients in Phase IIb trial.
